CD96/TACTILE[Biotin], His & Avi, Human

CD96/TACTILE[Biotin], His & Avi, Human

The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development.
Z04076
¥123,118.00

Ask us a question
Product Introduction
Species Human
Protein Construction
CD96/TACTILE (Val22-Met503)
Accession # P40200-2		 His Avi
N-term C-term
Conjugate Biotin
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized Anti­CD96 Antibody, hFc Tag at 1μg/ml (100μl/well) on the plate can bind CD96/TACTILE[Biotin], His & Avi, Human. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 59.1 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 115-140 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development.
Synonyms CD96 molecule; CD96; DKFZp667E2122; TACTILE

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.